tradingkey.logo
tradingkey.logo
Search

Fresenius Medical Care AG

FMS
Add to Watchlist
23.590USD
+0.015+0.06%
Close 06/18, 16:00ETQuotes delayed by 15 min
6.59BMarket Cap
12.59P/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
4.80
Change
0
The current earnings forecast score of Fresenius Medical Care AG is 4.80, ranking 68 out of 76 in the Healthcare Providers & Services industry. The average price target is 28.00, with a high of 39.65 and a low of 20.70.

Analyst Rating

Based on 5 analysts
Sell
Current Rating
25.632
Target Price
+8.65%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

68
Total
8
Median
9
Average
Company name
Ratings
Analysts
Fresenius Medical Care AG
FMS
5
CVS Health Corp
CVS
29
Teladoc Health Inc
TDOC
27
HCA Healthcare Inc
HCA
26
Natera Inc
NTRA
23
Tenet Healthcare Corp
THC
23
1
2
3
...
14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Fresenius Medical Care AG's expected revenue for the next quarter?

Fresenius Medical Care AG's expected revenue is 5.36B.

What is Fresenius Medical Care AG's price target?

Analysts forecast that Fresenius Medical Care AG's price target is USD 28.00, with the highest forecast at USD 39.65 and the lowest forecast at USD 20.70.

How have Fresenius Medical Care AGFMS's recent earnings per share performed?

The market expectation was USD 0.25, while Fresenius Medical Care AGFMS's earnings per share (EPS) for the previous quarter was USD 0.67. EPS for the next quarter is expected at USD 0.53.

What is the analyst rating for Fresenius Medical Care AG?

Based on the ratings of Fresenius Medical Care AG's stock from 5 analysts, most analysts support a Sell trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Sell. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI